Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

@article{Gansevoort2016RecommendationsFT,
  title={Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice},
  author={R. Gansevoort and M. Arıcı and T. Benzing and H. Birn and G. Capasso and A. Covic and O. Devuyst and C. Drechsler and K. Eckardt and F. Emma and B. Knebelmann and Y. Le Meur and Z. Massy and A. Ong and A. Ortiz and F. Schaefer and R. Torra and R. Vanholder and A. Więcek and C. Zoccali and W. van Biesen},
  journal={Nephrology Dialysis Transplantation},
  year={2016},
  volume={31},
  pages={337 - 348}
}
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to… Expand

Paper Mentions

Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Management of autosomal-dominant polycystic kidney disease—state-of-the-art
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Autosomal dominant polycystic kidney disease: updated perspectives
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.
Polycystic kidney disease: a 2011 update
  • T. Steinman
  • Medicine
  • Current opinion in nephrology and hypertension
  • 2012
Imaging for the prognosis of autosomal dominant polycystic kidney disease
...
1
2
3
4
5
...